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ABSTRACT
Background Several studies have suggested potential
links of phthalates to obesity in children and adults.
Limited evidence, however, has been available for the
relations between diethylhexyl phthalate (DEHP) and
obesity-related markers or body mass change in early
life.
Methods 128 healthy pregnant women were recruited
and, after delivery, their newborns’ ﬁrst urine and
umbilical cord blood samples were collected. We
measured urinary levels of two DEHP metabolites, mono-
(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) and mono-
(2-ethyl-5-oxohexyl) phthalate (MEOHP). We also
measured the levels of leptin, total cholesterol and
triglyceride (TG) in cord serum, and used them along
with weight, length, head circumference and ponderal
index (PI, 100 g/cm3) at birth, as obesity-related
markers, and estimated the relations between DEHP
metabolites and obesity-related markers using
generalised linear models. For the evaluation of body
mass increase by early life DEHP exposure, body mass
index (BMI) z-score change during 3 months after birth
by DEHP metabolites in the ﬁrst urine samples of the
newborns were evaluated using logistic regression.
Results DEHP exposure was associated with decrease
of PI and increase of TG (PI, β=−0.11, p=0.070 and
TG, β=0.14, p=0.027), especially for boys (PI, β=
−0.13, p=0.021; and TG, β=0.19, p=0.025). Moreover,
DEHP exposure was positively associated with body mass
increase during 3 months after birth (change of BMI
z-scores, OR=4.35, p=0.025).
Conclusions Our ﬁndings suggest that DEHP exposure
may affect body mass change in early life through
changes of obesity-related markers.
INTRODUCTION
Phthalates have been known to contribute to a high
prevalence of various symptoms including obesity
and diabetes mellitus.1 Among phthalates, diethyl-
hexyl phthalate (DEHP) has been used as a domin-
ant plasticiser of polyvinyl chloride-containing
products. Since DEHP is easily separated from
plastic, people are frequently exposed to it. Owing
to its potential adverse effects on human health
and humans’ ubiquitous exposure to it, the
European Union has put DEHP under regulation2
and California, in 2009, banned its use in chil-
dren’s toys.3 Although several reports have
suggested a signiﬁcant association between phthal-
ate exposures and obesity in children and adults,1 4
little is known about how DEHP causes obesity in
humans and whether DEHP exposure affects
obesity development in early life as well as in child-
hood and adulthood.1 5 6
Many studies reported DEHP metabolite levels
in each medium of pregnant women, cord blood
and breast milk, and suggested that exposure to
DEHP in early life may be no less important than
exposure later in life.7–10 Recently, early-life expos-
ure to endocrine disruptors including DEHP was
suggested to cause permanent metabolic altera-
tions,11 potentially increasing the chance of obesity
later in life, and leading to various diseases such as
hypertension and diabetes mellitus.6
In the present study, we investigated whether
exposure to DEHP is associated with
obesity-related markers and, by extension, whether
its perinatal exposure might affect body mass
change in early life. Therefore, we measured levels
of DEHP metabolites in newborns’ urine as well as
maternal blood, maternal urine, placenta and cord
blood samples, and evaluated the effects of DEHP
exposure on obesity-related markers and body mass
change for the ﬁrst 3 months after birth.
METHODS
Study population and sampling
The Children’s Health and Environmental
Chemicals in Korea (CHECK) Study was launched
in January 2011, to explore relationships between
environmental exposures and health outcomes in
children. Totally, 335 pregnant women with a
healthy mature singleton were recruited based on
volunteering, from the general population at ﬁve
university hospitals in Seoul, Pyungchon, Ansan
and Jeju, Republic of Korea. We selected 128
women among them, who gave birth between
February and December, 2012, and used the stand-
ard operating procedure described earlier for
sample collection/treatment. Detailed information
of the participants was obtained through
face-to-face interviews with a structured question-
naire, for personal characteristics and pregnancy-
related information, including age, weight, height,
income, gestational period, caesarean section and
past delivery experience. Body weight, length and
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head circumference of the newborns were measured directly
after birth, and weight and length 3 months after birth were
ascertained later through a telephone interview. Blood and urine
samples of the pregnant women were collected as soon as they
came to hospital on the day before delivery, and placenta along
with umbilical cord blood were collected during delivery; the
newborns’ ﬁrst urine samples were collected by nurses, using
polyethylene urine-collection bags (Urine Collector, ROOTICS
Corp, Korea) within 2 days postpartum. Maternal and cord
blood was directly collected in a serum separation tube (SST),
using a needle connected to a vacutainer made from polyethyl-
ene (BD Vacutainer SST II Advance, ref # 367953,
Becton-Dickinson, UK), and centrifuged at 3000 rpm for
10 min. The serums were then transferred to a 1 mL polyethyl-
ene cryotube with screw cap. All samples were stored at −80°C
until analysis. Each study participant provided written informed
consent. The study protocol was conducted in accordance with
guidelines laid down in the Declaration of Helsinki, and all pro-
cedures were approved by the Institutional Review Board at
School of Public Health, Seoul National University, Korea (IRB
number 8-2012-04-20).
Measurement of DEHP metabolites
Based on the recommendation for selecting exposure biomar-
kers of DEHP,12 we selected mono-(2-ethyl-5-hydroxyhexyl)
phthalate (MEHHP) and mono-(2-ethyl-5-oxohexyl) phthalate
(MEOHP), metabolites of DEHP as DEHP exposure markers.
Levels of MEHHP and MEOHP were measured in blood, urine
and placenta samples using procedures presented in online sup-
plementary methods.13–16 Information regarding quality
assurance and control are described in online supplementary
methods and tables S1–S4.
Measurement of leptin, total cholesterol and triglyceride (TG)
The levels of leptin, total cholesterol and TG in cord serum
were measured as obesity-related markers by procedures pre-
sented in online supplementary methods.17
Statistical analyses
Basic characteristics in newborn boys and girls were compared
using a t test or χ2 test. DEHP metabolite concentrations under
limit of detection (LOD) were assigned as a default value of LOD
divided by √2. Distribution of DEHP metabolites in blood, pla-
centa and urine samples, and ratios of DEHP metabolites in new-
borns’ and mothers’ samples, were analysed. The associations
among DEHP metabolite levels in maternal blood, maternal
urine, cord blood, placenta and newborns’ urine samples, were
estimated using Spearman correlation. The effect of DEHP meta-
bolites in newborns’ urine on obesity-related markers and body
mass index (BMI) change was evaluated using a generalised linear
model, where the common log of each level of obesity-related
markers (birth weight, birth length, head circumference at birth,
ponderal index (PI, 100 g/cm3), leptin, total cholesterol and TG)
was regressed on the corresponding common log of the DEHP
metabolites in the newborn’s ﬁrst urine by the newborn’s sex
after adjustment for maternal age (years), maternal BMI (kg/m2),
gestational period (days), caesarean section (0—no/1—yes), delivery
experience (0—no/1—yes) and urinary creatinine level (mg/dL). To
evaluate the change of body mass for the ﬁrst 3 months after
birth by DEHP exposure, we calculated change of BMI z-scores,
Dzi ¼ ððBMI0  BMI0iÞ=SD0Þ  ððBMI3  BMI3iÞ=SD3Þ, where
BMI0 and BMI3 were the mean BMIs at birth and the third
month, BMI0i and BMI3iwere individual BMIs at birth and the
third month, and SD0 and SD3 were standard deviations of
BMIs at birth and the third month, respectively, and then evalu-
ated the effects of the common log of the urinary biomarkers of
DEHP on the change of BMI z-score using logistic regression
after adjustment for covariates used in the generalised linear
model plus newborn’s sex (0—girl/1—boy), common log of PI
(100 g/cm3) and common log of TG (mg/dL). The evaluation
criterion for relative body mass increase was BMI z-score
change (Dzi) more than the 50th centile.
All analyses used two-sided tests, with a p value lower than
0.05 as statistically signiﬁcant. SAS V.9.4 Enterprise (SAS
Institute Inc, Cary, North Carolina, USA) and R V.3.1.2 (The
Comprehensive R Archive Network: http://cran.r-project.org)
were used for statistical analyses.
RESULTS
A total of 128 healthy pregnant women and their newborns
(65 boys and 63 girls) were included in this study. Leptin levels
in cord blood were signiﬁcantly different between boys and girls
(p=0.002), while others were not different (table 1).
DEHP metabolite concentrations were measured in maternal
blood (n=105), maternal urine (n=116), cord blood (n=101),
placenta (n=115) and newborns’ urine (n=73) samples (table 2).
While MEOHP was detected in all urine samples but not in those
of most blood and placenta, MEHHP was detected in all sample
media. Geometric mean (GM) was 0.31 ng/mL for MEHHP in
maternal blood, 18.23 ng/mL for MEHHP and 15.88 ng/mL for
MEOHP in maternal urine, 0.33 ng/mL for MEHHP in cord
blood, 0.10 ng/g for MEHHP in placenta and 5.83 ng/mL for
MEHHP, and 3.02 ng/mL for MEOHP in newborns’ urine
samples (table 2). GM for MEOHP in blood samples was not
Table 1 Characteristics of the participants
Newborn’s sex (median (IQR) or
n (%))
Characteristics Boys (n=65) Girls (n=63) p Value
Maternal age (years) 33 (30–36) 34 (32–38) 0.083
Maternal body mass index
(kg/m2)
20 (19–23) 20 (19–22) 0.816
Gestational period (days) 275 (268–280) 277 (270–282) 0.277
Caesarean section
No 46 (70.8) 41 (65.1) 0.490
Yes 19 (29.2) 22 (34.9)
Delivery experience
No 17 (26.2) 16 (25.4) 0.922
Yes 48 (73.8) 47 (74.6)
Income (US$/month)
1000–2999 17 (28.3) 14 (26.9) 0.891
3000–5999 27 (45.0) 22 (42.3)
≥6000 16 (26.7) 16 (30.8)
Birth weight (kg) 3.3 (3.1–3.5) 3.2 (3.1–3.4) 0.272
Birth length (cm) 50 (49–52) 50 (48–52) 0.584
Head circumference at birth
(cm)
34 (33–35) 34 (33–35) 0.133
Ponderal index (100 g/cm3) 2.5 (2.2–2.9) 2.5 (2.1–2.8) 0.886
Leptin in cord blood (ng/mL) 3.7 (2.4–5.8) 6.5 (4.2–13.8) 0.002
Total cholesterol in cord blood
(mg/dL)
63 (51–72) 70 (59–81) 0.339
Triglyceride in cord blood
(mg/dL)
30 (24–42) 28.5 (25–37) 0.509
Creatinine (mg/dL) 42 (28.0–65.3) 33 (22.9–58.6) 0.299
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calculated due to small samples detected above LOD. MEHHP
was relatively dominant over MEOHP in all media—88% in
maternal blood, 53.4% in maternal urine, 88.3% in cord blood,
77.5% in placenta and 65.7% in newborns’ urine samples.
In order to take an empirical overview of relative metabolite
distribution among mother-baby pairs, newborn-to-mother
ratios of the metabolites were summarised as GM (geometric
SD, GSD) and 90th centile as follows: 1.04 (0.17) and 1.27 for
MEHHP in blood, 0.48 (0.62) and 1.32 for MEHHP in urine,
and 0.28 (0.36) and 0.76 for MEOHP in urine (see online
supplementary table S5).
We also estimated the association among individual metabo-
lites in maternal blood, maternal urine, cord blood, placenta
and newborns’ urine samples (table 3). MEHHP showed signiﬁ-
cantly positive correlations among all media (all, p<0.05)
except for the marginal signiﬁcance in the relation between cord
blood and placenta samples (p=0.052). MEOHP levels also
showed signiﬁcantly positive correlations between maternal
blood and cord blood, and between maternal urine and new-
borns’ urine (both, p<0.05), but showed negative correlation
between maternal urines and cord bloods samples (p=0.001).
Interestingly, MEOHP levels in maternal urine and newborns’
urine samples were found to be positively associated with
MEHHP levels in all media (all, p<0.05).
The effects of each DEHP metabolite and sum of MEHHP
and MEOHP (∑DEHP) on obesity-related markers are sum-
marised in table 4. Urinary MEHHP and MEOHP levels were
negatively associated with PIs (MEHHP, β=−0.11, p=0.066;
and MEOHP, β=−0.10, p=0.083), and positively associated
with TG levels (MEHHP, β=0.15, p=0.024; and MEOHP,
β=0.13, p=0.042). In summary, urinary levels of ∑DEHP were
also negatively associated with PIs and positively associated with
TG levels (PI, β=–0.11, p=0.070; and TG, β=0.14, p=0.027;
decrease of 127 g/cm3 (48%) of PI and increase of 1.39 mg/dL
(4.6%) of TG by increase of 10 ng/mL of ∑DEHP). The nega-
tive association of DEHP metabolites with PIs was more appar-
ent in boys (MEHHP, β=−0.13, p=0.022; MEOHP, β=−0.13,
p=0.020; and ∑DEHP, β=−0.13, p=0.021).
Regarding body mass change during the ﬁrst 3 months after
birth, urinary DEHP metabolites were positively associated with
changes of BMI z-scores from birth to 3 months after birth
(β=0.88, p<0.001; see online supplementary table S6), and
both MEHHP and MEOHP showed a signiﬁcantly increased
odds ratio (OR) for body mass increase over the 50th centile
(MEHHP, OR=4.43, p=0.023; MEOHP, OR=3.91, p=0.032;
and ∑DEHP, OR=4.35, p=0.025; table 5).
DISCUSSION
One of the features of the present study is that we used all avail-
able biological tissues from matched mother-newborn pairs. We
explored the distribution of exposure biomarkers of DEHP
among the tissues, and tried to investigate relationship between
perinatal DEHP exposure and potential health outcomes linked
to obesity in early life.
In this study, we evaluated MEHHP and MEOHP levels as
DEHP exposure markers. Urinary DEHP metabolite concentrations
in the present study were higher than those in a study of German
mothers and their healthy newborns (median, 5.6 ng/mL for
MEHHP and 4.8 ng/mL for MEOHP in mothers, and 1.7 ng/mL
for MEHHP and 1.3 ng/mL for MEOHP in newborns),18 but
similar to those in full-term infants from birth to 14 months of
age in a study from Finland (median, 5.01 ng/mL for MEHHP
and 3.90 ng/mL for MEOHP).19 We found more abundance of
MEHHP relative to MEOHP in all media, which was consistent
with other studies on newborns from days 2–5, children at 2 or
5 years old and pregnant women,18 20 21 and partly supported
by a human pharmacokinetic study with oral administration of
deuterium-labelled DEHP.22 23
In the estimation of relations among media for DEHP metab-
olite levels, MEHHP and MEOHP levels in our study showed
generally good correlations among media, particularly for
MEHHP. Although MEOHP levels showed positive correlations
between maternal blood and cord blood, and between maternal
urine and newborns’ urine, negative correlation was also found
between maternal urine and cord blood for MEOHP. It may be
due to small samples detected for MEOHP in cord blood.
Therefore, positive correlations of MEOHP levels between
maternal and cord blood and negative correlation between
maternal urine and cord blood should be carefully interpreted.
However, positive correlations of MEHHP levels among media,
Table 2 DEHP metabolite concentrations of the study population
Percentile
Metabolite n n>LOD (%) GM (GSD) 10th 25th 50th 75th 90th
Maternal blood
MEHHP (ng/mL) 105 105 (100) 0.31 (0.05) 0.27 0.29 0.31 0.33 0.39
MEOHP (ng/mL) 105 1 (1.0) – <LOD <LOD <LOD <LOD <LOD
Maternal urine
MEHHP (ng/mL) 116 116 (100) 18.23 (28.82) 5.03 10.39 17.74 37.97 60.42
MEOHP (ng/mL) 116 116 (100) 15.88 (27.58) 4.93 9.33 14.70 29.55 52.41
Cord blood
MEHHP (ng/mL) 101 101 (100) 0.33 (0.05) 0.28 0.30 0.32 0.35 0.39
MEOHP (ng/mL) 101 2 (2.0) – <LOD <LOD <LOD <LOD <LOD
Placenta
MEHHP (ng/g) 115 115 (100) 0.10 (0.02) 0.08 0.08 0.09 0.11 0.14
MEOHP (ng/g) 115 1 (0.9) – <LOD <LOD <LOD <LOD <LOD
Newborns’ urine
MEHHP (ng/mL) 73 73 (100) 5.83 (10.79) 1.33 3.21 5.79 11.87 19.08
MEOHP (ng/mL) 73 73 (100) 3.02 (6.15) 0.64 1.51 3.27 6.50 10.00
DEHP, diethylhexyl phthalate; GM, geometric mean; GSD, geometric SD; MEHPP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate.
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and positive correlation of MEOHP levels between maternal
and newborns’ urine, support urinary metabolites in newborns
presenting perinatal exposure to DEHP. Moreover, the ratio of
MEHHP in cord serum and in maternal serum can allow us to
empirically compare MEHHP levels in newborn samples with
those in maternal samples, which provides an insight into how
much DEHP (or DEHP metabolite) was transferred from
mothers to their fetuses. MEHHP levels in cord serums were
similar or slightly higher relative to those in maternal blood. To
the contrary, both MEHHP and MEOHP in newborns’ ﬁrst
urine had relatively lower levels compared to those in the mater-
nal urine. This may be due to a lower proﬁle of oxidised meta-
bolites in newborns’ urine because of the immature metabolism
and renal function of newborns.24
Several epidemiological studies have shown positive associa-
tions between exposure to phthalates and increased obesity in
children and adults.1 4 Since PI has been commonly used as a
valid index for the body density of newborns due to it having
dimensions similar to those of density, we tested relations
between DEHP metabolites and obesity-related markers at birth,
including PI, and found signiﬁcant decrease of PI and increase
of TG by DEHP exposure. Since decreased PI and increased TG
have been considered as risk factors for obesity after birth and
in adults,25 and lipid proﬁle including TG was changed in the
DEHP-treated Sprague-Dawley rats,26 27 we evaluated body
mass change during 3 months after birth after controlling for
body mass increase accompanying infant growth and conﬁrmed
a signiﬁcantly relative body mass increase during the 3 months
after birth by DEHP exposure, supporting the contention that
DEHP exposure in early life may increase the development of
obese infants resulting in higher rate of obesity-related diseases.
Moreover, exposure to DEHP in our study showed a marginally
signiﬁcant association for reduced leptin level after adjustment
for newborns’ sex (data not shown here). Leptin is a hormone
produced by adipocytes, and indicates the systematic amount of
body fat.25 28 In several prospective cohort studies, concentra-
tions of cord or maternal blood leptin were positively related to
PI at birth but inversely related to weight gain in children at 1,
2, 3 and 5 years of age, supporting the contention that low con-
centrations of leptin at birth may provide a signal for an acceler-
ation of body mass increase.25 29–31 Furthermore, in our study,
the leptin in cord serum mainly produced by the adipose tissue
of the fetus32 was higher in girls than in boys, supported by a
basically higher leptin level in girls than in boys in non-obese
children at the ages of 5 and 15 years and newborns.33 34
Kennedy et al35 suggested that, in the feedback regulatory loop
between leptin and the brain, the ‘set point’ responding for
leptin in women seems to be higher than that in men, due to a
basically higher leptin level in women than in men, and thus, in
women, greater concentrations of leptin are required to close
the regulatory loop at the hypothalamus. However, the sex-
related difference of leptin levels was not associated with
weight, height, age or adiposity.33 Therefore, the more apparent
decrease of PI by DEHP exposure among boys in our study may
be due to the difference of ‘set point’ responding for leptin,
between boys and girls.
We did not adjust for newborns’ diet in our model although it
could be an important factor affecting body mass of infants,
because type and amount of postnatal dietary intake were exam-
ined only in half of our subjects. However, when we controlled
the type and amount of postnatal dietary intake in our models,
we found bigger OR for BMI z-score increase by DEHP expos-
ure although it was not signiﬁcant due to small sample size (data
not shown here). Moreover, breast milk as another DEHP
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exposure source was fed after ﬁrst urine collection in the
present study and thus it may not affect perinatal DEHP expos-
ure in newborns. Furthermore, we used the same procedure of
caring for newborns before urine collection to rule out other
DEHP exposure factors. In addition, we checked the difference
between DEHP metabolites by sources of DEHP exposure plaus-
ible during delivery and after birth, for example, between
regular and caesarean births, and among ﬁve hospitals, because
DEHP may be used for some medical products.36 However, we
did not ﬁnd any difference between regular and caesarean
births, and among hospitals (data not shown here).
The strength of the present study was the cohort design using
various media. This study design allows for the evaluation of the
effects of DEHP exposures on obesity-related markers and body
mass change in early life. While only healthy newborns, not
those who were obese or without low birth weight, were
included in this study, we found signiﬁcant associations of
urinary DEHP metabolite levels in newborns with obesity-related
markers and body mass change in early life. Since DEHP meta-
bolites in urine are known to be valid exposure biomarkers com-
pared with those in other media,12 we used urinary levels of
MEHHP and MEOHP as exposure biomarkers in newborns to
evaluate DEHP exposure in early life. However, we also found
good correlation between the levels of MEHHP and MEOHP in
newborns’ urine and those in various media, indicating a possi-
bility representing in utero DEHP exposure in newborns.
On the other hand, our study had limitations as well. We
did not consider temporality of exposure to DEHP although
DEHP metabolites have been considered as representative of
acute exposures due to their short half-life. However, DEHP
measures were reproducible from one day to the next in spite
of a great deal of variability in DEHP exposure because life-
style habits may not change quickly.37 38 Since we got informa-
tion such as gestational age, weight and length of infants at
birth and at 3 months basically by interviewing, not by review-
ing medical charts, information bias could not be ruled out.
However, such an error is likely to be non-differential, which
generally shifts the associations toward the null. In addition,
we did not consider other endocrine disrupting chemicals
(EDCs) except DEHP. Because EDCs known to be obesogens
including persistent organic pollutants, bisphenol A, and other
phthalates except for DEHP may be co-exposed to participants
of the present study,39 40 mixed effects of EDCs should be
further studied in the future.
Table 4 The effects of DEHP metabolites in newborns’ urine on obesity-related markers
Exposure Outcome
Total
p Value
Boys
p Value
Girls
p Valueβ
95% CI
β
95% CI
β
95% CI
Lower Upper Lower Upper Lower Upper
MEHHP Birth weight −0.003 −0.038 0.032 0.872 −0.003 −0.052 0.045 0.895 −0.020 −0.074 0.034 0.483
Birth length 0.031 −0.006 0.068 0.104 0.048 0.015 0.080 0.008 −0.044 −0.136 0.048 0.378
Head circumference at birth 0.004 −0.010 0.017 0.586 −0.0004 −0.021 0.020 0.970 0.013 −0.004 0.030 0.166
Ponderal index at birth −0.105 −0.215 0.004 0.066 −0.129 −0.233 −0.026 0.022 0.045 −0.253 0.344 0.774
Leptin in cord blood −0.069 −0.360 0.221 0.642 0.083 −0.198 0.365 0.567 −0.440 −1.271 0.391 0.334
Total cholesterol in cord blood −0.021 −0.104 0.062 0.620 −0.010 −0.114 0.094 0.857 −0.044 −0.168 0.080 0.502
Triglyceride in cord blood 0.146 0.024 0.267 0.024 0.188 0.036 0.340 0.022 0.050 −0.191 0.291 0.695
MEOHP Birth weight 0.002 −0.033 0.037 0.897 0.003 −0.046 0.052 0.901 −0.021 −0.075 0.033 0.471
Birth length 0.030 −0.007 0.067 0.115 0.052 0.019 0.085 0.004 −0.042 −0.132 0.048 0.388
Head circumference at birth 0.006 −0.007 0.019 0.381 0.003 −0.018 0.024 0.768 0.013 −0.004 0.030 0.158
Ponderal index at birth −0.099 −0.209 0.010 0.083 −0.133 −0.239 −0.028 0.020 0.037 −0.255 0.329 0.810
Leptin in cord blood −0.039 −0.332 0.254 0.795 0.080 −0.209 0.370 0.591 −0.323 −1.175 0.528 0.481
Total cholesterol in cord blood −0.014 −0.098 0.070 0.744 −0.008 −0.114 0.098 0.883 −0.032 −0.157 0.093 0.629
Triglyceride in cord blood 0.132 0.009 0.256 0.042 0.181 0.024 0.338 0.032 0.025 −0.217 0.266 0.845
∑DEHP Birth weight −0.001 −0.036 0.035 0.960 −0.001 −0.050 0.048 0.976 −0.021 −0.075 0.034 0.480
Birth length 0.031 −0.006 0.068 0.104 0.050 0.017 0.082 0.006 −0.044 −0.136 0.048 0.374
Head circumference at birth 0.005 −0.009 0.018 0.502 0.001 −0.020 0.022 0.935 0.013 −0.004 0.031 0.157
Ponderal index at birth −0.105 −0.215 0.006 0.070 −0.132 −0.236 −0.027 0.021 0.044 −0.256 0.344 0.779
Leptin in cord blood −0.059 −0.353 0.235 0.697 0.085 −0.200 0.371 0.564 −0.410 −1.260 0.439 0.375
Total cholesterol in cord blood −0.019 −0.103 0.065 0.657 −0.009 −0.114 0.096 0.868 −0.041 −0.167 0.085 0.539
Triglyceride in cord blood 0.144 0.020 0.267 0.027 0.188 0.034 0.342 0.025 0.042 −0.202 0.287 0.742
The effect of DEHP metabolites in newborns’ urine on the obesity-related markers was evaluated using a generalised linear model, where the common log of each level of
obesity-related markers (birth weight (kg), birth length (cm), head circumference at birth (cm), ponderal index (PI, 100 g/cm3), leptin (ng/mL), total cholesterol (mg/dL) and TG (mg/dL)),
was regressed on the corresponding common log of the DEHP metabolites (ng/mL) in the newborn’s first urine after adjustment for maternal age (years), maternal BMI (kg/m2),
gestational period (days), caesarean section (0—no/1—yes), delivery experience (0—no/1—yes) and urinary creatinine level (mg/dL). ∑DEHP, sum of MEHHP and MEOHP.
DEHP, diethylhexyl phthalate; MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate.
Table 5 Change of BMI z-scores from birth to 3 months after
birth by change of DEHP metabolites
95% CI
Exposure OR Lower Upper p Value
MEHHP 4.43 1.22 16.04 0.023
MEOHP 3.91 1.12 13.65 0.032
∑DEHP 4.35 1.20 15.72 0.025
The effect of common log of DEHP metabolite in newborns’ urine on the change of
BMI z-score was evaluated using logistic regression after adjustment for covariates
used in the generalised linear model plus newborns’ sex (0—girl/1—boy), common
log of ponderal index (PI, 100 g/cm3) and common log of triglyceride (TG, mg/dL).
Evaluation criterion for relative body mass increase was BMI z-score change over the
50th centile. ∑DEHP, sum of MEHHP and MEOHP.
BMI, body mass index; DEHP, diethylhexyl phthalate; MEHHP,
mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl)
phthalate.
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In conclusion, this study suggests that DEHP exposure may
decrease PI and increase TG levels in newborn infants, ﬁnally
resulting in body mass increase in early life. However, further
epidemiological studies with large sample sizes are needed to
conﬁrm our ﬁndings.
What is already known on this subject
▸ Phthalate has been suggested to increase obesity in children
and adults.
▸ Obesity in early life is associated with obesity later in life
leading to development of obesity-related diseases.
▸ Limited evidence has been available for the relations
between diethylhexyl phthalate (DEHP), a dominant
plasticiser, and obesity-related markers or body mass change
in early life.
What this study adds
▸ Exposure to DEHP is associated with decrease of ponderal
index and increase of triglyceride at birth.
▸ Body mass increase is accelerated in newborn infants
exposed to DEHP.
▸ Given the association of DEHP with obesity-related markers
and body mass change in early life, efforts in reducing DEHP
exposure in early life may be important for potentially
decreasing the chance of obesity later in life leading to
various diseases.
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